Humanwell Healthcare (600079.SH): Brexpiprazole Tablets Obtain Drug Registration Certificate

15:37 06/08/2026

ST Renfu (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu," in which the company holds an 80% stake) recently received the "Drug Registration Certificate" for Brivaracetam Tablets issued by the National Medical Products Administration.

Humanwell Healthcare (600079.SH) announced that its subsidiary, Yichang Rendu Pharmaceutical Co., Ltd. (referred to as "Yichang Rendu," in which the company holds an 80% stake), recently received the drug registration certificate for Brexpiprazole from the National Medical Products Administration. Brexpiprazole is primarily used for the treatment of adult schizophrenia. Yichang Rendu submitted its application for market approval of Brexpiprazole to the National Medical Products Administration in April 2025, which has been accepted. To date, the total R&D investment for this project has amounted to approximately 18 million RMB.

WANGUO GOLD GP (03939) plans to issue convertible bonds with a total principal amount of HKD 5.5 billion.

ZTO EXPRESS-W (02057) announced its mid-term performance, with net profit attributable to shareholders increasing by 31.5% year-on-year to 5.169 billion yuan, continuously enhancing service quality and operational efficiency.

ZTO EXPRESS-W (02057): Both volume and quality have improved, with Q2 business volume reaching 10.5 billion pieces, a growth of 6.5%, and a market share of 19.9%.

WANGUO GOLD GP (03939) plans to issue convertible bonds with a total principal amount of HKD 5.5 billion.

ZTO EXPRESS-W (02057): Both volume and quality have improved, with Q2 business volume reaching 10.5 billion pieces, a growth of 6.5%, and a market share of 19.9%.